Enliven Therapeutics ELVN Non Cash Lease Expense
Non Cash Lease Expense at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept elvn:NonCashLeaseExpense.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's non cash lease expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's non cash lease expense?
- Enliven Therapeutics (ELVN) reported non cash lease expense of $93K in Q1 2026.
- How has Enliven Therapeutics's non cash lease expense changed year-over-year?
- Enliven Therapeutics's non cash lease expense increased by 9.4% year-over-year, from $85K to $93K.
- What is the long-term trend for Enliven Therapeutics's non cash lease expense?
- Over 2 years (2023 to 2025), Enliven Therapeutics's non cash lease expense has grown at a 7.4% compound annual growth rate (CAGR), from $306K to $353K.
- What does non cash lease expense mean?
- This represents the portion of lease expenses recognized in the income statement that does not involve an immediate cash outflow. It is added back to net income in the operating cash flow section to reconcile accounting profit with actual cash generated from operations.